Ketamine Versus ECT: Why the Trial Population Changes the Headline

Evidence scope: Prepared for an October 30, 2026 editorial reference date using the dated primary sources linked below. This is not an exhaustive search through that date; later evidence, corrections, and regulatory decisions require a fresh check before publication. No claim of current approval or availability is implied.

Disclosure: This article is not diagnosis, treatment advice, or a substitute for individualized care. Do not change treatment based on this article.

A comparative trial can be more useful than two separate success stories. Instead of asking whether people improved after one intervention, it asks what happened when similar eligible participants were assigned to different options. The 2023 trial of intravenous ketamine versus electroconvulsive therapy offers that kind of evidence for treatment-resistant major depression without psychosis. Its importance lies in the defined comparison, not in a headline claiming that one treatment has replaced another.

The primary New England Journal of Medicine report describes an open-label randomized noninferiority design. Participants had been referred to ECT clinics. During the initial three-week phase, one group received intravenous ketamine and the other ECT. The primary outcome was response, defined by a substantial reduction on a self-reported depression scale. This was not a placebo-controlled demonstration, a study of every depressive disorder, or a direct evaluation of intranasal esketamine.

Read the endpoint before the percentage

The reported response rates were 55.4 percent with ketamine and 41.2 percent with ECT. Those numbers can be informative while still being easy to misread. Response is not the same as remission, recovery of functioning, or permanent benefit. It is a threshold on a specified outcome at a specified time. Someone may have a large improvement and still experience substantial symptoms, so a response percentage cannot describe the whole clinical experience.

Noninferiority also has a technical meaning. Investigators prespecify a margin that represents an unacceptable loss of benefit relative to the comparison. Their analysis then evaluates whether the new option falls within that boundary. The finding does not become a universal superiority claim simply because the observed percentage is numerically higher in one group. Readers should examine the prespecified framework rather than substitute an informal ranking based on the raw percentages alone.

Why psychosis is not a minor exclusion

The trial excluded psychotic depression. That boundary changes the interpretation because a result in one population cannot establish the relative effects in a clinically different population. A headline saying that ketamine works as well as ECT for depression omits a crucial qualifier. A more accurate summary retains both treatment resistance and the absence of psychosis, alongside the initial treatment period and the specific ketamine formulation used in the study.

The same principle applies to illness severity, coexisting conditions, and prior treatment history. Being eligible for a clinical trial often involves more than having a diagnostic label. A person considering these options should ask whether the study's participants resemble their own situation and whether the proposed treatment resembles the trial protocol. The existing guide to treatment-change conversations provides a starting point without converting trial criteria into self-selection instructions.

Open-label does not mean uninformative

Randomization strengthens the comparison by reducing systematic baseline differences between assigned groups. The open-label design remains relevant because participants knew which procedure they received, and the primary outcome used self-report. Expectations and preferences can influence reported experiences. That limitation does not make the result worthless. It means the study should be interpreted as a randomized comparison under its actual conditions, not described as if participants and treating teams were blinded.

ECT technique and delivery also matter. An intervention category can contain meaningful variations, and one comparison does not exhaust them all. Likewise, intravenous racemic ketamine is not interchangeable with all oral, compounded, or intranasal products. Readers should resist attempts to transfer the evidence to a different formulation without an appropriate evidentiary bridge. The site's esketamine coverage addresses a separate evidence question and should not be treated as a second report of this same intervention.

Burdens and follow-up belong in the comparison

The trial assessed more than depression symptoms, including memory-related outcomes and adverse effects. Those measures help explain why a person might value one option differently from another. They do not establish that either treatment is harmless. Meaningful comparison requires asking what was assessed, when it was assessed, and whether the study was large and long enough to detect uncommon or delayed problems. Short-term tolerability should not be rewritten as a lifetime safety guarantee.

A patient-centered discussion also includes travel, time, support needs, monitoring, and what happens if improvement fades. The trial's initial outcome cannot settle every maintenance question. Continued care and repeat treatment may affect later outcomes, so a clinic should explain its follow-up pathway separately from its initial-course claims. Our broader rapid depression care pillar examines why durability and access deserve the same attention as speed.

What future comparisons should add

The next useful studies would clarify which patient characteristics alter relative benefit, how results translate across care settings, and how treatment strategies perform over longer periods. They should report functioning, quality of life, harms, and additional treatment as clearly as early symptom response. These are not secondary concerns for someone deciding how to organize months of care; they are part of what effectiveness means in ordinary life.

The responsible conclusion is neither that ECT is obsolete nor that ketamine is an interchangeable substitute in every situation. The trial supports a specific comparative finding in nonpsychotic treatment-resistant depression. It gives patients and clinicians better evidence for a bounded conversation. It does not provide a self-treatment protocol or establish suicide prevention. When an immediate safety concern exists, urgent professional assessment takes priority over interpreting a study or waiting for a particular intervention.

Sources

• Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression

For general medicine-safety background, see NIMH mental health medications; this is background, not independent confirmation of this article’s specific study.